Neurocetam Syrup: Each 5 mL contains piracetam 0.5 g.
Neurocetam Injection: Each mL contains piracetam 200 mg and water for injection qs.
Piracetam is 2-(2-oxopyrolidin-1-yl) acetamide.
Nootropic agent, a new category of drug acting on central nervous system.
Pharmacology: Piracetam improves the cerebral microcirculation by increasing erythrocytes deformability and inhibiting platelet aggregation. It increases regional glucose metabolism in the cerebral cortex, basal ganglia and cerebellum in patients with ischaemic stroke. It also modulates central cholinergic neurotransmission and enhances the efficiency of cortical control over subcortical structures.
Neurocetam Injection: Piracetam, a nootropic agent, directly improves the efficiency of the higher telencephalic functions of the brain involved in the cognitive processes eg, those related to learning, memory, thought and consciousness, both in normal and deficient situations, without being a sedative or psychostimulant.
Mechanism of Action: Piracetam exerts those various activities by different ways of action. It modulates brain neurotransmission and enhances neuronal metabolism by increasing glucose and oxygen uptake.
It improves microcirculation through antispasmodic and haemorrheological properties without being a vasodilator.
Pharmacokinetics: Piracetam is rapidly absorbed when administered orally; peak serum concentration is reached in 45 min. The half-life after oral administration is 4.5 hrs. There is no risk of accumulation. Piracetam crosses the blood-brain barrier and is found in CSF in 2 hrs. Its half-life in CSF is 7.5 hrs. Piracetam is excreted to the extent of about 97% in the urine in the unchanged form.
Cerebrocortical insufficiency disorders or states eg, trauma or surgery, alcoholism, vertigo, cerebrovascular accidents and behavioural disorders in children.
As an adjunct in the treatment of myoclonic seizures and in senile dementia. Piracetam protects the cerebral cortex against hypoxia.
Neurocetam Injection: Cerebrovascular accidents.
Post Traumatic Syndromes: Cerebral dysfunctions related to post-traumatic sequelae eg, headache, vertigo, agitation and memory asthenia.
Involutional Syndromes Related to Ageing: Memory deficits, particularly with regard to fixation and evocation, asthenia, adaptation disorders and disturbed psychomotor reactions.
Behavioral disorders and learning disability in children (dyslexia), in combination with language therapy.
Cortical myoclonus.
Recurrent or chronic vertigo/postconcussion vertigo.
Tablet/Capsule: Cerebro-Cortical Insufficiency Disorders: 800-1000 mg 3 times daily by mouth.
Myoclonic Seizures: 7.2 g daily increasing by 4.8 g daily every 3-4 days up to a maximum of 20 g daily. It is given by mouth in 2 or 3 divided doses.
Syrup: 2-3 tsp, 2-3 times a day.
Injection: Cerebrovascular Accidents: Acute Stage: 9-12 g daily in 3 or 4 divided doses for 2-4 weeks.
Subacute and Chronic States: 4.8-6 g daily.
Psycho-organic Syndromes: Treatment should begin at 4.8 g/day reducing to 2.4 g/day.
Dyslexia: Children 8-13 years: 3.3 g daily in 2 divided doses for at least 1 full school year.
Vertigo: 2.4-4.8 g daily in 2-3 divided doses.
Cortical Myoclonus: The dosage should commence at 7.2 g daily, increasing by 4.5 g daily every 3-4 days to a maximum of 20 g daily in 2 or 3 divided doses.
Other antimyoclonic medications should continue at the same dosage.
Doses as high as 400 mg/kg bodyweight have been reported and well tolerated. No specific treatment is indicated. Forced diuresis (oral or IV) is recommended.
Patients with severe renal insufficiency (creatinine clearance <20 mL/min) and in patients hypersensitive to piracetam.
Piracetam should not be given to patients with hepatic dysfunction or severe renal impairment. Dosage reductions are recommended for patients with lesser degrees of renal impairment. Therapy with piracetam should not be withdrawn abruptly.
Piracetam is reported to inhibit platelet aggregation and reduce blood viscosity at high doses.
Neurocetam Injection: Piracetam is eliminated via the renal route; care should thus be taken in cases of renal insufficiency. In these patients, the increased half-life is inversely related to creatinine clearance. The table shows the dose reductions corresponding to creatinine clearance <60 mL/min.
Click on icon to see table/diagram/image
Abrupt discontinuation of treatment should be avoided in myoclonic patients, as this may induce myoclonic or generalised seizures.
Use in pregnancy & lactation: Reproduction studies in animals have not identified any risk to the foetus. No studies in pregnant women have, however, been reported. Thus, as for all medications, the physician should evaluate the potential benefits of treatment, especially during the 1st trimester and during lactation.
Reproduction studies in animals have not identified any risk to the foetus. No studies in pregnant women have, however, been reported. Thus, as for all medications, the physician should evaluate the potential benefits of treatment, especially during the 1st trimester and during lactation.
Piracetam is reported to produce insomnia or somnolence, weight gain, nervousness and depression. Diarrhoea and rashes may occur at a lower frequency.
Neurocetam Injection: Adverse reactions that have been reported during treatment are: Nervousness, irritability, insomnia, anxiety, tremor and agitation. Some patients have reported fatigue and somnolence. In most cases, a dose reduction is sufficient to eliminate adverse reactions altogether.
Gastrointestinal disorders (nausea, vomiting, diarrhoea, gastralgia), headaches and vertigo have also been reported. The following have also been occasionally reported: Dry mouth, increased libido, weight gain and mainly dermatological hypersensitivity reactions.
Prothrombin time is increased when patients stabilised on warfarin are treated with piracetam.
Neurocetam Injection: Only one case of confusion, irritability and sleep disorder has been reported during concomitant treatment with thyroid extract (T3+T4).
At present, no interaction has been documented with the following antiepileptic medications: Clonazepam, carbamazepine, phenytoin, phenobarbitone and sodium valproate. There is no interaction with acetyl salicylic acid. To date, there are no known interactions with other medications.
Store in a cool, dry place.
N06BX03 - piracetam ; Belongs to the class of other psychostimulants and nootropics.
Cap 400 mg x 10 x 10's. FC tab 800 mg x 10 x 10's. Syr 500 mg/5 mL x 100 mL x 1's. Inj (amp) 200 mg/mL x 15 mL x 4's.
Sign Out
